

Georgi Iskrov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2868115/publications.pdf>

Version: 2024-02-01

42
papers

807
citations

516215

16
h-index

552369

26
g-index

42
all docs

42
docs citations

42
times ranked

1116
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. <i>Value in Health</i> , 2019, 22, 1283-1288.	0.1	97
2	Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 19-29.	1.4	59
3	Social/economic costs and quality of life in patients with haemophilia in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 53-65.	1.4	53
4	Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 31-42.	1.4	50
5	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 89-98.	1.4	41
6	Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 79-87.	1.4	40
7	Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 7-18.	1.4	38
8	Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs. <i>Frontiers in Public Health</i> , 2016, 4, 214.	1.3	35
9	Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 43-52.	1.4	35
10	Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 99-108.	1.4	31
11	National Registries of Rare Diseases in Europe: An Overview of the Current Situation and Experiences. <i>Public Health Genomics</i> , 2015, 18, 20-25.	0.6	30
12	Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria. <i>Health Policy</i> , 2012, 108, 10-18.	1.4	29
13	Social/economic costs and health-related quality of life in patients with scleroderma in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 109-117.	1.4	28
14	Access to orphan drugs – comparison across Balkan countries. <i>Health Policy</i> , 2018, 122, 583-589.	1.4	20
15	Real-World Experiences in Autistic Adult Diagnostic Services and Post-diagnostic Support and Alignment with Services Guidelines: Results from the ASDEU Study. <i>Journal of Autism and Developmental Disorders</i> , 2021, 51, 4129-4146.	1.7	20
16	Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria. <i>Balkan Medical Journal</i> , 2016, 33, 27-35.	0.3	17
17	Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs. <i>Folia Medica</i> , 2013, 55, 80-86.	0.2	16
18	Social/economic costs and health-related quality of life in patients with histiocytosis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 67-78.	1.4	16

#	ARTICLE	IF	CITATIONS
19	Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations. <i>Orphan Drugs: Research and Reviews</i> , 2014, , 1.	0.6	15
20	Economic Burden And Health-Related Quality Of Life Of Patients With Cystic Fibrosis In Bulgaria. <i>Folia Medica</i> , 2015, 57, 56-64.	0.2	15
21	Health Technology Assessment and Appraisal of Therapies for Rare Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 221-231.	0.8	13
22	Schooling of Children with Rare Diseases and Disability in Europe. <i>International Journal of Disability Development and Education</i> , 2019, 66, 362-373.	0.6	11
23	Intervention Services for Autistic Adults: An ASDEU Study of Autistic Adults, Carers, and Professionalsâ€™ Experiences. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 1623-1639.	1.7	10
24	Prospects of Risk-Sharing Agreements for Innovative Therapies in a Context of Deficit Spending in Bulgaria. <i>Frontiers in Public Health</i> , 2015, 3, 64.	1.3	9
25	Local Anesthesia in Pediatric Patients â€“ a Review of Current and Alternative Methods, Devices and Techniques. <i>Folia Medica</i> , 2018, 60, 381-388.	0.2	9
26	Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion. <i>Frontiers in Pharmacology</i> , 2016, 7, 252.	1.6	8
27	Transposition and implementation of EU rare disease policy in Eastern Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 557-566.	0.7	8
28	Whole-Genome Sequencing in Newborn Screeningâ€™ Attitudes and Opinions of Bulgarian Pediatricians and Geneticists. <i>Frontiers in Public Health</i> , 2017, 5, 308.	1.3	8
29	Autistic Adult Health and Professional Perceptions of It: Evidence From the ASDEU Project. <i>Frontiers in Psychiatry</i> , 2021, 12, 614102.	1.3	8
30	What Is the Value of Innovative Pharmaceutical Therapies in Oncology and Hematology? A Willingness-to-Pay Study in Bulgaria. <i>Value in Health Regional Issues</i> , 2019, 19, 157-162.	0.5	7
31	Practice Patterns for Early Screening and Evaluation for Autism Spectrum Disorder Diagnosis in Bulgaria. <i>Journal of Autism and Developmental Disorders</i> , 2021, 51, 778-789.	1.7	7
32	Socio-Economic Burden of Myasthenia Gravis: A Cost-of-Illness Study in Bulgaria. <i>Frontiers in Public Health</i> , 2022, 10, 822909.	1.3	6
33	Health systems for rare diseases: financial sustainability. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2019, 55, 270-275.	0.2	5
34	Ensuring Transparency and Consistency in the Value Assessment of Cancer Therapies. <i>Journal of Clinical Oncology</i> , 2016, 34, 2938-2939.	0.8	3
35	What could gene therapies learn from orphan drugsâ€™ post-regulatory approval access in the EU?. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 407-414.	0.5	3
36	Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia. <i>Hospital Pharmacology</i> , 2016, 3, 422-434.	0.1	2

#	ARTICLE	IF	CITATIONS
37	Autistic Adult Services Availability, Preferences, and User Experiences: Results From the Autism Spectrum Disorder in the European Union Survey. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
38	European Network of Rare Disease Help Lines (ENRDHLs) â€“ caller profile analysis 2013. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, O13.	1.2	1
39	RARE-Bestpractices: a platform for sharing best practices for the management of rare diseases. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, O14.	1.2	1
40	National Plans on Rare Diseases. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , 1-22.	0.6	1
41	PP071 Health Technology Assessment In Bulgaria: A Review Of The First Fifteen Reports Assessed. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 103-104.	0.2	0
42	Authorsâ€™ reply to Rare diseases in Romania â€“ a response to â€“Transposition and implementation of EU rare diseases policy in Eastern Europeâ€™. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 349-350.	0.7	0